These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 12384539

  • 1. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C, Kornacker M, Scheffold YC, Contag CH, Negrin RS.
    Cancer Res; 2002 Oct 15; 62(20):5785-91. PubMed ID: 12384539
    [Abstract] [Full Text] [Related]

  • 2. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK, Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM, Schulz S, Thorne SH, Teng NN, Contag CH, Lum LG, Negrin RS.
    Clin Cancer Res; 2006 Mar 15; 12(6):1859-67. PubMed ID: 16551871
    [Abstract] [Full Text] [Related]

  • 3. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A, Mezzanzanica D, Jung G, Wolf H, Colnaghi MI, Canevari S.
    Cancer Res; 1996 Dec 01; 56(23):5443-9. PubMed ID: 8968099
    [Abstract] [Full Text] [Related]

  • 4. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T, Nakamura Y, Takeuchi Y, Tokuda Y, Iwasawa M, Kawasaki A, Okumura K, Habu S.
    J Immunol; 1992 Jan 01; 148(1):285-91. PubMed ID: 1345787
    [Abstract] [Full Text] [Related]

  • 5. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab.
    Kornacker M, Verneris M, Kornacker B, Ganten T, Scheffold C, Negrin R.
    Cytotherapy; 2006 Jan 01; 8(1):13-23. PubMed ID: 16627341
    [Abstract] [Full Text] [Related]

  • 6. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
    Chapoval AI, Nelson H, Thibault C.
    J Immunol; 1995 Aug 01; 155(3):1296-303. PubMed ID: 7636196
    [Abstract] [Full Text] [Related]

  • 7. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
    Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG.
    Clin Cancer Res; 2006 Jan 15; 12(2):569-76. PubMed ID: 16428502
    [Abstract] [Full Text] [Related]

  • 8. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY.
    J Immunol; 1994 Mar 01; 152(5):2385-92. PubMed ID: 8133049
    [Abstract] [Full Text] [Related]

  • 9. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
    Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, Mangold S, Rau D, Meier P, Kiener PA, Mulgrew K, Oberst MD, Hammond SA, Baeuerle PA, Kufer P.
    J Immunother; 2009 May 01; 32(4):341-52. PubMed ID: 19342971
    [Abstract] [Full Text] [Related]

  • 10. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H, Li F, Gordon JR, Xiang J.
    Cancer Res; 2002 Apr 01; 62(7):2043-51. PubMed ID: 11929823
    [Abstract] [Full Text] [Related]

  • 11. Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model.
    Mezzanzanica D, Garrido MA, Neblock DS, Daddona PE, Andrew SM, Zurawski VR, Segal DM, Wunderlich JR.
    Cancer Res; 1991 Oct 15; 51(20):5716-21. PubMed ID: 1833054
    [Abstract] [Full Text] [Related]

  • 12. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
    Konishi J, Yamazaki K, Yokouchi H, Shinagawa N, Iwabuchi K, Nishimura M.
    Hum Immunol; 2004 Nov 15; 65(11):1377-88. PubMed ID: 15556688
    [Abstract] [Full Text] [Related]

  • 13. Activation and preferential expansion of rat cytotoxic (CD8) T cells in vitro and in vivo with a bispecific (anti-TCR alpha/beta x anti-CD2) F(ab')2 antibody.
    Tutt AL, Reid R, Wilkins BS, Glennie MJ.
    J Immunol; 1995 Sep 15; 155(6):2960-71. PubMed ID: 7673714
    [Abstract] [Full Text] [Related]

  • 14. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
    Ren-Heidenreich L, Davol PA, Kouttab NM, Elfenbein GJ, Lum LG.
    Cancer; 2004 Mar 01; 100(5):1095-103. PubMed ID: 14983507
    [Abstract] [Full Text] [Related]

  • 15. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
    Cesson V, Stirnemann K, Robert B, Luescher I, Filleron T, Corradin G, Mach JP, Donda A.
    Clin Cancer Res; 2006 Dec 15; 12(24):7422-30. PubMed ID: 17189415
    [Abstract] [Full Text] [Related]

  • 16. Immunotherapy with bispecific antibodies.
    Thielemans KM.
    Verh K Acad Geneeskd Belg; 1995 Dec 15; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
    [Abstract] [Full Text] [Related]

  • 17. Bispecific F (ab')2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells.
    Nitta T, Yagita H, Azuma T, Sato K, Okumura K.
    Eur J Immunol; 1989 Aug 15; 19(8):1437-41. PubMed ID: 2528460
    [Abstract] [Full Text] [Related]

  • 18. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
    Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, Kinch MS, Coats S, Baeuerle PA, Kufer P, Kiener PA.
    Cancer Res; 2007 Apr 15; 67(8):3927-35. PubMed ID: 17440108
    [Abstract] [Full Text] [Related]

  • 19. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I.
    Cancer Res; 1993 Jan 01; 53(1):94-100. PubMed ID: 8093231
    [Abstract] [Full Text] [Related]

  • 20. CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro.
    Molema G, Tervaert JW, Kroesen BJ, Helfrich W, Meijer DK, de Leij LF.
    Br J Cancer; 2000 Jan 01; 82(2):472-9. PubMed ID: 10646907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.